non-small cell lung cancer
Conditions
Interventions
1:SRS and almonertinib combination
Sponsors
Henan Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Non-small cell lung cancer with EGFR mutations proved by pathological examinations; 2. the brain metastatic sites are less than 5 proved by CT or MRI examinations, or the brain metastatic is stable after treatment with the first/second generation EGFR-TKIs, or the brain metastatic sites are less than 5 after treatment with the first/second generation EGFR-TKIs; 3. after receiving systemic treatment, the primary and metastatic tumors are stable and no new progress shows at least 2 weeks; 4. all the oligometastatic sites should be suitable for SRS treatment.
Exclusion criteria
Exclusion criteria: 1. Patients diagnosed with other kind of cancers at the same time; 2. The primary and metastatic tumors have been irradiated; 3. Pregnant or breast-feeding female patients; 4. The tumor boundary could not be defined; 5. Patients with respiratory failure; 6. Patients and their caregivers refused to participate; 7. Patients with severe inflammation or other serious diseases; 8. Allergic to the study drugs; 9. Patients who has been involved in other clinic trails; 10. Patients defined as not suitable by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Five-year disease-free survival;intracranial progression-free survival (iPFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR);Overall survival (OS);progression-free survival (PFS); | — |
Countries
China
Contacts
Public ContactHe chunyu
Henan Cancer Hospital
Outcome results
None listed